As constitutive activation of P-Src has been determined in head and neck squamous cell carcinoma, and blockade of Src signaling has been shown to effectively inhibit cell growth and induce apoptosis in head and neck squamous cell carcinoma cells, we hypothesized that Dasatinib would be useful in treating human laryngeal cancer cells. Here, SRC is linked to laryngeal carcinoma.